Vraylar 3mg capsules?

What is Vraylar 3mg capsule?

Vraylar 3mg capsule is a medication prescribed to treat schizophrenia and bipolar disorder. It belongs to a class of drugs known as antipsychotics, specifically a partial dopamine agonist.

How does Vraylar work?

Vraylar works by affecting the levels of certain chemicals in the brain, such as dopamine and glutamate. It is thought to help stabilize mood and reduce symptoms of schizophrenia and bipolar disorder by modulating these chemicals' activity [1].

Is Vraylar available as a generic or biosimilar?

No, Vraylar does not have an FDA-approved generic or biosimilar available in the market yet. However, its exclusivity is set to expire in 2030 [2] based on data from DrugPatentWatch.com. This may change, as manufacturers may file for approval of generic or biosimilar versions.

Common side effects of Vraylar

Common side effects of Vraylar 3mg capsule include dizziness, drowsiness, headache, nausea, and vomiting. Less common side effects may include changes in appetite, weight gain, and increased salivation.

Potential risks and warnings

Vraylar may cause QT prolongation (a heart condition) in rare cases. Patients with a history of heart problems or those taking other medications that may increase the risk of QT prolongation should use caution when taking Vraylar. The medication may also interact with other medications, such as antidepressants and other antipsychotics.

How to take Vraylar 3mg capsule

Vraylar capsules should be taken by mouth with or without food. It is essential to follow the dosing instructions provided by your healthcare provider, as the recommended dose may vary depending on the individual's needs.

References:

[1] - Alpharma Inc. (2015). Vraylar (cariprazine) Capsules.

[2] - DrugPatentWatch.com (n.d.). Cariprazine patents. Retrieved from https://www.drugpatentwatch.com/results.php?skeyword=cariprazine